把三张表、经营指标、SEC / 巨潮 / 港交所原始财报、业绩材料和电话会放到同一条可核验时间线上。 披露事实、结构化补位值与派生指标分开标注，缺失逐字稿不会用摘要或模型生成内容补齐。
单季、累计、年度和资产负债表时点分开保存；每个数值都保留单位、申报日、表单、XBRL 概念或原始中文字段。
美股链接 SEC 法定申报和发行人 IR，A 股链接巨潮原始 PDF，港股链接港交所披露易原始年报与中报。分部、订单、产能和客户集中度只在有可核验披露时展示。
官方电话会入口与已授权逐字稿分开。没有合法取得的全文时只显示材料可用性，不生成或拼接虚假的逐字稿。
三张表会执行资产负债、毛利润、税前利润等勾稽检查；超出容差的记录保留原值并标记警告， 不会为了让公式“对上”而修改公司披露。
| 2026-06-30 |
| 3/3 |
| $1.47B |
| -$183M |
| $892M |
| 80.1% |
| -15.6% |
| 59 |
| 尚无授权文本 |
| CALX CALIX, INC | 2026-06-27 | 3/3 | $293.33M | $17.11M | $18.45M | 54.6% | 7.4% | 75 | 尚无授权文本 |
| PLXS PLEXUS CORP | 2026-04-04 | 3/3 | $1.16M | $49.81M | -$34.57M | 10240.6% | 5313.6% | 70 | 尚无授权文本 |
| ALX ALEXANDERS INC | 2026-03-31 | 3/3 | $53.41M | $4.66M | — | — | — | 42 | 尚无授权文本 |
| ALXO ALX ONCOLOGY HOLDINGS INC | 2026-03-31 | 3/3 | — | -$17.93M | -$18.7M | — | — | 85 | 尚无授权文本 |
| AMLX Amylyx Pharmaceuticals, Inc. | 2026-03-31 | 3/3 | — | -$41.28M | — | — | — | 68 | 尚无授权文本 |
| ATLX Atlas Lithium Corp | 2026-03-31 | 3/3 | $84,797 | -$13.56M | -$11.84M | 85.0% | -19803.1% | 77 | 尚无授权文本 |
| CDLX Cardlytics, Inc. | 2026-03-31 | 3/3 | $34.32M | -$4.48M | -$5.67M | — | -24.1% | 102 | 尚无授权文本 |
| CLX CLOROX CO /DE/ | 2026-03-31 | 3/3 | $1.67B | $187M | $161M | 43.2% | — | 83 | 尚无授权文本 |
| DLX DELUXE CORP | 2026-03-31 | 3/3 | $538.1M | $35.8M | $27.3M | 51.9% | 13.3% | 97 | 尚无授权文本 |
| FLXS FLEXSTEEL INDUSTRIES INC | 2026-03-31 | 3/3 | $115.13M | $6.45M | $23.66M | 22.6% | 7.1% | 75 | 尚无授权文本 |
| GLXY Galaxy Digital Inc. | 2026-03-31 | 3/3 | $10.01B | -$216.31M | — | — | — | 29 | 尚无授权文本 |
| GNLX GENELUX Corp | 2026-03-31 | 3/3 | — | -$8.93M | -$6.98M | — | — | 45 | 尚无授权文本 |
| HLX HELIX ENERGY SOLUTIONS GROUP INC | 2026-03-31 | 3/3 | $287.95M | -$13.41M | — | 3.1% | -4.6% | 93 | 尚无授权文本 |
| HLXC Helix Acquisition Corp. III | 2026-03-31 | 3/3 | — | $840,973 | — | — | — | 4 | 尚无授权文本 |
| INLX INTELLINETICS, INC. | 2026-03-31 | 3/3 | $3.91M | -$1.18M | -$253,398 | 63.5% | -30.3% | 85 | 尚无授权文本 |
| KLXE KLX Energy Services Holdings, Inc. | 2026-03-31 | 3/3 | $144.7M | -$24M | -$8.4M | 17.7% | -8.4% | 92 | 尚无授权文本 |
| LXEO Lexeo Therapeutics, Inc. | 2026-03-31 | 3/3 | — | -$20.2M | -$21.18M | — | — | 46 | 尚无授权文本 |
| LXP LXP Industrial Trust | 2026-03-31 | 3/3 | $972,000 | -$239,000 | — | -1621.7% | — | 90 | 尚无授权文本 |
| LXRX LEXICON PHARMACEUTICALS, INC. | 2026-03-31 | 3/3 | $21.1M | -$1.04M | — | 99.5% | -4.7% | 101 | 尚无授权文本 |
| MPLX MPLX LP | 2026-03-31 | 3/3 | $2.35B | $922M | $772M | — | 51.7% | 81 | 尚无授权文本 |
| OFLX Omega Flex, Inc. | 2026-03-31 | 3/3 | $23.09M | $2.08M | -$101,000 | 56.7% | 10.0% | 87 | 尚无授权文本 |
| PLX Protalix BioTherapeutics, Inc. | 2026-03-31 | 3/3 | $33.75M | $18.32M | $21.26M | 87.8% | 62.7% | 101 | 尚无授权文本 |
| SCLX Scilex Holding Co | 2026-03-31 | 3/3 | $8.61M | -$45.65M | — | 298.4% | -373.5% | 164 | 尚无授权文本 |
| SLXN Silexion Therapeutics Corp | 2026-03-31 | 3/3 | — | -$2.73M | -$3.65M | — | — | 77 | 尚无授权文本 |
| TSLX Sixth Street Specialty Lending, Inc. | 2026-03-31 | 3/3 | — | -$26.03M | — | — | — | 85 | 尚无授权文本 |
| LXFR LUXFER HOLDINGS PLC | 2026-03-29 | 3/3 | $83.9M | $3.6M | -$6.1M | 26.1% | 7.4% | 95 | 尚无授权文本 |
| DLXY Delixy Holdings Ltd | 2025-12-31 | 3/3 | $307.75M | -$4.46M | — | 0.8% | -1.5% | 9 | 尚无授权文本 |
| FLX BingEx Ltd | 2025-12-31 | 3/3 | $570.86M | $15.65M | $14.14M | 11.8% | 1.2% | 10 | 尚无授权文本 |
| LX LexinFintech Holdings Ltd. | 2025-12-31 | 3/3 | $1.88B | $239.82M | $466.39M | 34.0% | — | 47 | 尚无授权文本 |
| LXEH Lixiang Education Holding Co. Ltd. | 2025-12-31 | 3/3 | $4.41M | -$17.43M | -$44.96M | -38.7% | -118.0% | 54 | 尚无授权文本 |
| NCEL NewcelX Ltd. | 2025-12-31 | 3/3 | — | -$8.3M | -$2.77M | — | — | 216 | 尚无授权文本 |
| RELX RELX PLC | 2025-12-31 | 2/3 | — | — | — | — | — | 636 | 尚无授权文本 |
| RLX RLX Technology Inc. | 2025-12-31 | 3/3 | $566.11M | $131.83M | $141.11M | 29.9% | 8.3% | 38 | 尚无授权文本 |
| TLX Telix Pharmaceuticals Ltd | 2025-12-31 | 2/3 | — | -$7.13M | — | — | — | 57 | 尚无授权文本 |
| GLXG Galaxy Payroll Group Ltd | 2025-06-30 | 3/3 | $3.49M | -$3.51M | -$3.54M | 42.6% | -101.2% | 19 | 尚无授权文本 |
| BLX BLADEX, INC. | 2024-12-31 | 2/3 | — | $205.87M | — | — | — | 125 | 尚无授权文本 |